Genmab Outlicenses Zanolimumab to TenX Biopharma
Genmab A/S announced that it has closed a license agreement under which Genmab has granted exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) to TenX Biopharma, Inc.
Under the terms of the agreement, Genmab receives a payment of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX Biopharma will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.
“Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate”, said Gardiner F.H. Smith, Chief Executive Officer of TenX Biopharma. “We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency”
Other news from the department business & finance
